TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05132881

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuvana 2.0 Transcutaneous Auricular Vagal Nerve Stimulation (TaVNS)
Description: The intervention administered is the TaVNS program and the fMRI scans to evaluate changes in the brain. The TaVNS program consists of placing ear buds from the device into each ear. They are initially sprayed once with a small amount of saline that is also provided as part of the TaVNS materials. Once the ear buds are placed in each ear, the test subject will start a preprogramed session of vibrations that will stimulate the vagus nerve. The session will last for 15 minutes and then the subject will take the ear buds out and clean them. They will use the TaVNS program once a day for 3 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control
Description: Baseline imaging and follow up imaging for comparison to the TaVNS health device group at approximately 3 months. The TaVNS intervention is offered after completion of the imaging.

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Controls: Substudy Group III
Description: fMRI Imaging to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device during one fMRI session.

Intervention type: OTHER
Group type: OTHER
Intervention: Distressed Workers: Subgroup II
Description: Subgroup II of 10 subjects with distress(all receiving TaVNS) will undergo fMRI scans with the TaVNS system being turned on and off while in the scanner to observe for any immediate effects and to evaluate the effects of the functional changes that may occur in the brain while using the TaVNS device during one fMRI session.
Study: NCT05302297

Intervention type: DRUG
Intervention: Cemiplimab
Description: Pharmaceutical Form: Concentrate solution for injection for intravenous (IV) infusion Route of Administration: Intravenous (IV) infusion

Intervention type: DRUG
Intervention: Cemiplimab
Description: Pharmaceutical Form: Concentrate solution for injection for intravenous (IV) infusion Route of Administration: Intravenous (IV) infusion
Study: NCT05743647

Intervention type: DEVICE
Intervention: Observation (OBS)
Description: Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject only observe the movement on the screen during the recordings. The subject does not produce any movement.

Intervention type: DEVICE
Intervention: Observation (OBS)
Description: Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject only observe the movement on the screen during the recordings. The subject does not produce any movement.

Intervention type: DEVICE
Intervention: Observation and imagination (OBS-IM)
Description: Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement but also imagine to realized it.

Intervention type: DEVICE
Intervention: Observation and imagination (OBS-IM)
Description: Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement but also imagine to realized it.
Study: NCT05370014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrating Community-based Intervention Under Nurse Guidance with Families (iCINGS FAM)
Description: The intervention consists of two planning sessions with the dyad (over 2 weeks) followed by eight topic-guided sessions delivered the RN-CHW team over 12 weeks (weekly the first 4 weeks, then bi-weekly) (Table 3). Key components of these televisits include COVID-19 risk mitigation, chronic disease management, medication adherence, family functioning/support, and community and health systems resource identification and referral with ongoing goal planning. The RN-CHW will meet weekly for progress review, follow up planning, and setting up anticipatory guidance for the next session with the dyads. The RN and CHW will also review IC or survivor dissatisfaction and other issues that require more immediate attention. RN-CHW planning will be assessed to make sure each televisit remain topic focused yet incorporates flexibility to suit the needs of each dyad.
Study: NCT05729204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic seawater solution
Description: Nasal irrigations with hypertonic seawater solution
Study: NCT04457596

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab Emtansine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06140394

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diode laser
Description: low level diode therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: diode laser
Description: low level diode therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non surgical scaling
Description: non surgical scaling using ultrasonic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non surgical scaling
Description: non surgical scaling using ultrasonic
Study: NCT06145425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: App-Delivered Mindfulness Training (MT)
Description: The program is delivered via a smartphone-based platform, which includes 7 mindfulness-based modules of about 15 minutes of brief didactic and experience-based mindfulness training (audio files).
Study: NCT05743647

Intervention type: DEVICE
Intervention: Observation and realization (OBS-REAL)
Description: Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement on the screen and realized it

Intervention type: DEVICE
Intervention: Observation and realization (OBS-REAL)
Description: Subject is seated in a chair facing IVS4. He places his right lower under the screen. The flexion / extension movement of the ankle at a frequency of 0.5 Hz is then recorded. Then for the mirror effect the software reverses the recorded movement, the lower right limb becomes the lower left limb on the screen.~The subject observe the movement on the screen and realized it
Study: NCT06321497

Intervention type: DEVICE
Intervention: Extracorporeal carbon dioxide removal
Description: Low flow extracorporeal carbon dioxide removal with PrismaLung+
Study: NCT05046106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLC1501
Description: Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLC1501
Description: Powdered extract of Radix astragali, Rhizoma chuanxiong, Radix angelica sinensis, Radix polygala

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Caramel, chocolate brown, flavor (E_1982648), dextrin
Study: NCT04966559

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naldemedine 0.2 MG Oral Tablet
Description: Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
Study: NCT05928663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: double surgical gloves
Description: In the intervention group, the surgical team members wore brown colored ENCORE® Latex Micro as the inner glove, while white MEDI-GRIP® Latex Standard was used as the outer glove

Intervention type: OTHER
Group type: OTHER
Intervention: single surgical gloves
Description: MEDI-GRIP® Latex Standard surgical gloves were included in the study as a single layer sterile surgical glove in the control group
Study: NCT03729713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive rehabilitation
Description: 6 week course of cognitive rehabilitation focused on attention, learning, and memory

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham placebo
Description: an alternative home-based computer program not designed for cognitive remediation but of the same duration
Study: NCT05563090

Intervention type: OTHER
Intervention: Questionnaires+Tongue diagnosis+Pulse diagnosis
Description: Each subject will undergo questionnaires, tongue and pulse diagnosis using modern diagnostic tools

Intervention type: OTHER
Intervention: Questionnaires+Tongue diagnosis+Pulse diagnosis
Description: Each subject will undergo questionnaires, tongue and pulse diagnosis using modern diagnostic tools

Intervention type: OTHER
Intervention: Questionnaires+Tongue diagnosis+Pulse diagnosis
Description: Each subject will undergo questionnaires, tongue and pulse diagnosis using modern diagnostic tools

Intervention type: OTHER
Intervention: Questionnaires+Tongue diagnosis+Pulse diagnosis
Description: Each subject will undergo questionnaires, tongue and pulse diagnosis using modern diagnostic tools

Intervention type: OTHER
Intervention: Questionnaires+Tongue diagnosis+Pulse diagnosis
Description: Each subject will undergo questionnaires, tongue and pulse diagnosis using modern diagnostic tools
Study: NCT04805957

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane comes from eating certain cruciferous vegetables. In this case the pills are made from broccoli seeds.
Study: NCT06209762

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The core stabilization exercise program, which is individually prescribed and structured, will be applied for 8 weeks. The level of exercises will be increased over time according to the patient's condition. Exercises will be taught to patients. It will be carried out under the supervision of a physiotherapist three days a week for 8 weeks. On the remaining days, the patient will be asked to do it himself.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The core stabilization exercise program, which is individually prescribed and structured, will be applied for 8 weeks. The level of exercises will be increased over time according to the patient's condition. Exercises will be taught to patients. It will be carried out under the supervision of a physiotherapist three days a week for 8 weeks. On the remaining days, the patient will be asked to do it himself.
Study: NCT06542406

Intervention type: DEVICE
Group type: OTHER
Intervention: Endotracheal intubation
Description: The first 40 successful and the first 40 unsuccessful ETE procedures were included in the study.
Study: NCT04749407

Intervention type: GENETIC
Intervention: biomarker detection
Description: PBMC and ctDNA analysis
Study: NCT04670770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug - SHR1459
Description: Oral Tablets taken once daily for 52 weeks
Study: NCT05176691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-760
Description: Administered orally QD for 28-day cycles
Study: NCT05259618

Intervention type: OTHER
Intervention: Tasso+ SST
Description: alternative site blood sample collection.
Study: NCT04283227

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OTL-200
Description: All subjects will receive OTL-200 gene therapy and will be followed up for 8 years following treatment with OTL-200.
Study: NCT05161741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Human rDNA Insulin (Insuget, local brand of Getz Pharma)
Study: NCT05026489

Intervention type: GENETIC
Intervention: G6PD gene deficiency
Description: we will use tetrazolazole-blue quantitative method to detect whether the patient suffer from G6PD deficiency.
Study: NCT05568368

Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study: NCT06239259

Intervention type: OTHER
Intervention: Questionare As described in Secondary Outcomes
Description: All patients will recieve Questionare As described in Secondary Outcomes, and will be interviewd by a well-trained reaserch assistanced
Study: NCT05276778

Intervention type: DIAGNOSTIC_TEST
Intervention: Diabetic Retinopathy Screening
Description: Screenings are performed in the diabetes consultation in general practice
Study: NCT06024915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ05105 tablets
Description: TQ05105 is a Janus kinase 2 (JAK2) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ05105 tablets
Description: TQ05105 is a Janus kinase 2 (JAK2) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole capsule
Description: Itraconazole is a strong inhibitor of cytochrome P450 3A (CYP3A).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin Capsule
Description: Rifampicin is a strong inducer of CYP3A.
Study: NCT06282640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D replacement therapy was administered at 50,000 IU weekly for 8 weeks.
Study: NCT06546150

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RE002 T cell
Description: All subjects who met the entry and exit criteria and signed the informed consent form were observed in hospital at the beginning of lymphocyte clearance chemotherapy, with the dosage of cyclophosphamide (600-800mg/m2/days,-5,-4 days) and fludarabine (25-30mg/m2/days,-5,-4,-3 days), at least two days after the completion of lymphocyte clearance chemotherapy.
Study: NCT06486142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afatinib/Dacomitinib
Description: Second-generation EGFR-inhibitors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Third-generation EGFR-inhibitor
Study: NCT05308277

Intervention type: DEVICE
Group type: OTHER
Intervention: Leo device monitoring
Description: After consent and enrollment, the child's respiratory impedance will be continuously recorded using the Leo device throughout the day and night during the entire hospital stay or ED visit. The device may be taken off for up to 1 hour per day (i.e., break during bath / shower time). The device will be applied to the skin overlying the mid-sternum area on the chest wall after cleaning of the skin with an alcohol swab after consent has been obtained. The device will be changed every 72 hours or earlier, by the participant's guardian, depending on signs of defect in the signal quality or battery exhaustion, based on daily check of the signal by the research team. Remote monitoring of the child's chest impedance will continue using the Leo device after discharge from hospital/ED for 7 days.
Study: NCT05764551

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum DNA methylation
Description: Serum DNA methylation
Study: NCT05113797

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lower Quarter Y-Balance Test
Description: Dynamic balance assessment performed in a standing position while balanced on one leg, participants are asked to move a plastic box with their other foot in three directions (forward, back to the left, and back to the right) and a distance measurement is recorded. Each leg will be tested three times in each direction for the YBT-LQ assessment.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lower Quarter Y-Balance Test
Description: Dynamic balance assessment performed in a standing position while balanced on one leg, participants are asked to move a plastic box with their other foot in three directions (forward, back to the left, and back to the right) and a distance measurement is recorded. Each leg will be tested three times in each direction for the YBT-LQ assessment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPTIMAL motor learning theory
Description: OPTIMAL theoretical framework instructions and coaching will be utilized to improve motor performance through three main components: promotion of autonomy support (AS), presence of an external focus (EF) of attention, and implementation of enhanced expectancies (EE) placed upon a task.
Study: NCT06351462

Intervention type: OTHER
Group type: OTHER
Intervention: Spermogram
Description: Spermogram will be proposed to men

Intervention type: OTHER
Group type: OTHER
Intervention: Spermogram
Description: Spermogram will be proposed to men

Intervention type: OTHER
Group type: OTHER
Intervention: Hospital Anxiety and Depression Scale (HADS)
Description: Anxiety and depression will be evaluated 10 years after HSCT

Intervention type: OTHER
Group type: OTHER
Intervention: Hospital Anxiety and Depression Scale (HADS)
Description: Anxiety and depression will be evaluated 10 years after HSCT

Intervention type: OTHER
Group type: OTHER
Intervention: SF36 Quality of life questionnaire
Description: Quality of life will be evaluated 10 years after HSCT

Intervention type: OTHER
Group type: OTHER
Intervention: SF36 Quality of life questionnaire
Description: Quality of life will be evaluated 10 years after HSCT

Intervention type: OTHER
Group type: OTHER
Intervention: Psychologist interview
Description: During a follow-up visit

Intervention type: OTHER
Group type: OTHER
Intervention: Psychologist interview
Description: During a follow-up visit

Intervention type: OTHER
Group type: OTHER
Intervention: Optional sera banking
Description: One in the study

Intervention type: OTHER
Group type: OTHER
Intervention: Optional sera banking
Description: One in the study

Intervention type: OTHER
Group type: OTHER
Intervention: Optional DNA banking
Description: Once in the study

Intervention type: OTHER
Group type: OTHER
Intervention: Optional DNA banking
Description: Once in the study
Study: NCT04759430

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Group
Description: Individuals will apply ten different stabilization exercises in company with a physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation group
Description: Same stabilization exercises will be performed online with the patient by the researcher physiotherapist and supervised through the video conference or phone.
Study: NCT04428008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin
Description: Synthetic 28 amino acid peptide
Study: NCT06097962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK510
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK510
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK510
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab，atezolizumab or sugemalimab
Description: Administer according to the instructions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab，atezolizumab or sugemalimab
Description: Administer according to the instructions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab，atezolizumab or sugemalimab
Description: Administer according to the instructions
Study: NCT06302595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-guided prostate biopsy using the needle holder frame.
Description: A needle holding frame will be used during a routine MRI-guided prostate biopsy procedure, where tissue samples are obtained from each suspected region found on MRI using an MRI-conditional core biopsy needle. In this routine procedure, tissue sampling is performed in an MRI gantry and intraprocedural MRI is used to localize the regions.
Study: NCT05096962

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative analysis of SARS-CoV-2 antibodies
Description: The study will evaluate the current presence of infection, specific antibodies at least in the IgG class in blood plasma or serum (antibody tests focusing on two SARS-CoV-2 proteins: S-protein and N-protein).

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative analysis of SARS-CoV-2 antibodies
Description: The study will evaluate the current presence of infection, specific antibodies at least in the IgG class in blood plasma or serum (antibody tests focusing on two SARS-CoV-2 proteins: S-protein and N-protein).

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative analysis of SARS-CoV-2 antibodies
Description: The study will evaluate the current presence of infection, specific antibodies at least in the IgG class in blood plasma or serum (antibody tests focusing on two SARS-CoV-2 proteins: S-protein and N-protein).

Intervention type: DIAGNOSTIC_TEST
Intervention: Cellular immunity
Description: Quantification of the level of cellular immunity from venous blood collected in approximately 30% of examined individuals.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cellular immunity
Description: Quantification of the level of cellular immunity from venous blood collected in approximately 30% of examined individuals.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cellular immunity
Description: Quantification of the level of cellular immunity from venous blood collected in approximately 30% of examined individuals.
Study: NCT06028386

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AC5® Advanced Wound System
Description: This group will receive AC5® Advanced Wound system, a synthetic self-assembling peptide matrix to the wound and covered with non-adherent dressing followed with appropriate outer dressing to maintain moisture balance. AC5 is applied weekly and outer dressing will be redressed as necessary.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fibracol Plus Collagen Dressing
Description: This group will receive Fibracol Plus collagen dressing to the wound and covered with appropriate out dressing. Treatment will be done 3x a week.
Study: NCT05645432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexanolone
Description: Brexanolone IV infusion